Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (NASDAQ: KTRA), based in San Diego, California, is a biopharmaceutical company focused on developing novel cancer therapies to address unmet medical needs. The company's core business involves the research and development of oncology drugs that target solid tumors. Kintara is currently advancing two late-stage, Phase 3-ready therapeutics: VAL-083 and REM-001. VAL-083 is a small-molecule chemotherapeutic with a unique mechanism of action, demonstrating clinical activity against a range of cancers including glioblastoma multiforme (GBM), central nervous system cancers, ovarian cancer, and other solid tumors. On the other hand, REM-001 is a photodynamic therapy (PDT) under evaluation for cutaneous metastatic breast cancer (CMBC).
In recent developments, Kintara has received an extension from Nasdaq to regain compliance with the Listing Rule 5550(b), ensuring they meet the required financial benchmarks. The company has also partnered with Ladenburg Thalmann & Co. Inc. to explore strategic alternatives aimed at maximizing shareholder value.
Recent Projects and Financial Health
Kintara launched a new 15-patient clinical trial for REM-001 for CMBC in February 2024, funded primarily by a $2.0 million grant from the National Institutes of Health (NIH). The trial aims to optimize dosage and study design ahead of a Phase 3 initiation. Financial results for the fiscal third quarter ended March 31, 2024, reveal a cash reserve of approximately $6.35 million, reflecting strengthened financials from recent stock sales and cost-cutting initiatives.
Another significant update is Kintara's planned merger with TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company. This all-stock transaction, expected to complete by Q3 2024, will result in a combined entity focused on advancing personalized cancer vaccines and bi-functional antibody drug conjugates, promising to overcome major obstacles in immunotherapy.
Conclusion
Kintara Therapeutics is dedicated to revolutionizing cancer treatment through innovative therapeutic solutions. With a robust pipeline, strategic partnerships, and a strong financial foundation, Kintara is poised to address significant gaps in cancer treatment and provide new hope to patients with limited options.
Kintara Therapeutics (Nasdaq: KTRA) has announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The company will present data on its investigational drug VAL-083, focused on treating RELA fusion-positive ependymoma and recurrent glioblastoma. Two abstracts will be shared: one detailing case studies of VAL-083 in patients with ependymoma and glioma under an expanded access program, and another highlighting findings from 24 recurrent glioblastoma patients. Kintara is dedicated to developing innovative cancer therapies, with VAL-083 currently being advanced in the GBM AGILE registrational study.
Kintara Therapeutics (Nasdaq: KTRA) announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 14-19 in Orlando. The company will present two posters focused on its lead program, VAL-083, aimed at treating recurrent glioblastoma. The presentations, on April 17, will cover case reports of RELA fusion-positive ependymoma and VAL-083’s application in glioblastoma patients under expanded access. Kintara, based in San Diego, is dedicated to developing novel cancer therapies to address significant medical needs.
Kintara Therapeutics, Inc. (NASDAQ: KTRA) announced its participation in two significant conferences in March 2023. At the 35th Annual ROTH Conference in Dana Point, CA, CEO Robert E. Hoffman will provide a corporate update on March 13 at 10:30 AM PT. Concurrently, at the 4th Annual Glioblastoma Drug Development Summit in Boston, MA, Dr. Dennis Brown and Greg Johnson will discuss Kintara's VAL-083 program for glioblastoma on March 15 at 4:00 PM ET. Kintara focuses on developing innovative cancer therapies, specifically VAL-083 for glioblastoma and REM-001 Therapy for cutaneous metastatic breast cancer.
Kintara Therapeutics, Inc. (NASDAQ: KTRA) reported its fiscal second-quarter financial results for the period ending December 31, 2022. The company has cash reserves of approximately $4.9 million and experienced a net loss of about $3.5 million, a decrease from $5.9 million in the same period last year. Key developments include receiving FDA Orphan Drug Designation for VAL-083, which targets untreated childhood brain cancer, and Fast Track Designation for REM-001 therapy in metastatic breast cancer. Kintara paused the REM-001 program to preserve cash, expecting to save around $3 million in 2023. Upcoming data from the GBM AGILE Study is anticipated by year-end.
FAQ
What is the current stock price of Kintara Therapeutics (KTRA)?
What is the market cap of Kintara Therapeutics (KTRA)?
What is the primary focus of Kintara Therapeutics?
What are Kintara's main therapeutic programs?
Where is Kintara Therapeutics based?
What recent financial developments has Kintara announced?
What strategic alternatives is Kintara exploring?
What is the significance of the REM-001 clinical trial?
Has Kintara received any grants for their clinical trials?
What is VAL-083 and what cancers does it target?
How is Kintara ensuring compliance with Nasdaq listing rules?
What potential benefits are expected from the merger with TuHURA Biosciences?
